Key Development

Cupid Limited's Board of Directors has accorded in-principle approval for the establishment of a manufacturing venture in South Africa with a South African partner. The approval was granted on August 28, 2026.

Venture Structure and Ownership

  • Proposed entity will manufacture, process, test, package, market and supply male condoms and related products
  • Cupid Limited expected to hold up to 49% of equity share capital
  • South African partner and/or its qualifying local shareholders would hold at least 51% and retain control
  • Structure designed to comply with South African ownership, localisation, transformation, procurement and tender requirements

Operational Model

  • Asset-light model for Cupid Limited
  • Company to contribute technical and manufacturing expertise, industry know-how, technology transfer support, quality-control systems, and training
  • South African partner to arrange capital expenditure for facility establishment and commissioning, along with working capital and operating funding

Strategic Rationale

  • Aligns with South Africa's emphasis on domestic manufacturing, localisation, supply-chain resilience and local value addition in healthcare supply chains
  • Supports development of local manufacturing capabilities, employment, skill development, and technology transfer
  • Provides platform for participation in domestic institutional and government procurement programs
  • Creates potential base for expansion across wider African market
  • May serve additional international markets over time, including Western Hemisphere markets
  • Could evolve into regional and global supply hub

Current Market Presence

Cupid Limited has been supplying the South African market for several years and currently participates through local business arrangements in the ongoing RT75-2025 five-year tender for male and female condoms.

Company Background

Established in 1993, Cupid Limited is described as "Bharat's leading healthcare and consumer wellness companies" with operations including:

  • Manufacturing and marketing of male and female condoms
  • Water-based personal lubricants
  • IVD kits
  • Consumer Healthcare & FMCG portfolio including fragrance products, personal care products, wellness products
  • First company in the world to receive WHO/UNFPA prequalification for both male and female condoms
  • Exports to 125+ countries
  • Serves global customers through PFSCM, WHO/UNFPA, institutional procurement programmes, government tenders and private export markets
  • Domestic presence through modern trade, organised retail and pharmacy channels
  • Expanding manufacturing capabilities through upcoming Palava manufacturing facility

Forward-Looking Statements

The document contains a disclaimer noting that certain statements are forward-looking and subject to risks including government actions, local/political/economic developments, technological risks, and other factors that could cause actual results to differ.